Process for producing cytotoxic lymphocyte
View Patent ↗The present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof.
1. A method for expanding cytotoxic lymphocytes which comprises:
culturing precursor cells, capable of differentiating to cytotoxic lymphocytes, wherein the precursor cells are selected from the group consisting of peripheral blood mononuclear cells and blood components containing these cells in the presence of at least one recombinant fibronectin fragment together with interleukin-2 and an anti-CD3 antibody,
wherein the recombinant fibronectin fragment is
a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 8 to 19,
wherein said culturing is performed for 2-15 days,
wherein the expanded cytotoxic lymphocytes maintain cytotoxic activity longer than cytotoxic lymphocytes expanded in the absence of at least one fibronectin fragment,
wherein said cytotoxic activity of the expanded cytotoxic lymphyocyte is evaluated as the cytotoxic activity against a target cell labeled with a fluorescent substance by determining fluorescent intensity ascribed to the target cell destroyed by said expanded cytotoxic lymphyocyte,
and wherein the expanded cytotoxic lymphocytes express more CD8 than cytotoxic lymphocytes expanded in the absence of at least one fibronectin fragment.
2. The method according to claim 1 , wherein the expanded cytotoxic lymphocytes highly express an interleukin-2 receptor at a higher level than cytotoxic lymphocytes expanded in the absence of at least one fibronectin fragment.
3. The method according to claim 1 , wherein said at least one recombinant fibronectin fragment is immobilized on a solid phase.
4. The method according to claim 3 , wherein the solid phase is a cell culture vessel or a cell culture carrier.
5. The method according to claim 4 , wherein the cell culture vessel is a petri dish, a flask or a bag, and the cell culture carrier is beads, a membrane or a slide glass.
6. The method according to claim 1 , wherein expanding a cytotoxic lymphocyte is performed in a cell culture medium comprising said recombinant fibronectin fragment or a mixture thereof.
7. The method according to claim 1 , comprising:
expanding a cytotoxic lymphocyte in a cell culture in the presence of said at least one recombinant fibronectin fragment,
wherein at least (a) or (b) is true:
(a) a ratio of the number of cells present at the initiation of the cell culture to a cell culture area is 1 cell/cm 2 to 5×10 5 cells/cm 2 ; and
(b) a concentration of cells at the initiation of the cell culture is from 1 cell/ml to 5×10 5 cells/ml.
8. The method according to claim 1 , further comprising transducing a foreign gene into the cytotoxic lymphocytes.
9. The method according to claim 8 , wherein the foreign gene is transduced using retrovirus, adenovirus, adeno-associated virus or simian virus.
10. The method according to claim 1 , wherein an expansion ratio of the cytotoxic lymphocytes is high as compared to that of a method for expanding cytotoxic lymphocytes in the absence of at least one fibronectin fragment.
11. The method according to claim 1 , wherein the fluorescent substance is calcein-AM.
12. The method according to claim 1 , wherein the precursor cells are cultured with the recombinant fibronectin fragment for four days after initiation of the culture.
13. The method according to claim 12 , wherein the expanded cytotoxic lymphocytes are capable of maintaining cytotoxic activity for 14 days.
14. A method for increasing the number of CD8-positive cells in a population of cytotoxic lymphocytes, which comprises:
culturing precursor cells, capable of differentiating to cytotoxic lymphocytes, wherein the precursor cells are selected from the group consisting of peripheral blood mononuclear cells and blood components containing these cells in the presence of at least one recombinant fibronectin fragment together with interleukin-2 and an anti-CD3 antibody, thereby increasing the number of CD8-positive cells in the cultured cells,
wherein the recombinant fibronectin fragment is
a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 8 to 19,
wherein said culturing is performed for 2-15 days,
wherein the cultured cytotoxic lymphocytes maintain cytotoxic activity longer than cytotoxic lymphocytes expanded in the absence of at least one fibronectin fragment,
and wherein said cytotoxic activity of the expanded cytotoxic lymphyocyte is evaluated as the cytotoxic activity against a target cell labeled with a fluorescent substance by determining fluorescent intensity ascribed to the target cell destroyed by said expanded cytotoxic lymphyocyte.
15. The method according to claim 14 , wherein the fluorescent substance is calcein-AM.
16. The method according to claim 14 , wherein the precursor cells are cultured with the recombinant fibronectin fragment for four days after initiation of the culture.
17. The method according to claim 16 , wherein the expanded cytotoxic lymphocytes are capable of maintaining cytotoxic activity for 14 days.